
## Tania C Sorrell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2136101/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases, 2008, 46, 1813-1821.	2.9	4,375
2	Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2010, 50, 291-322.	2.9	2,195
3	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	2.9	1,429
4	Epidemiology and Host- and Variety-Dependent Characteristics of Infection Due to Cryptococcus neoformans in Australia and New Zealand. Clinical Infectious Diseases, 2000, 31, 499-508.	2.9	421
5	Cryptococcus gattii Infections. Clinical Microbiology Reviews, 2014, 27, 980-1024.	5.7	327
6	Echinocandin Antifungal Drugs in Fungal Infections. Drugs, 2011, 71, 11-41.	4.9	324
7	Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Molecular Microbiology, 2001, 39, 166-175.	1.2	319
8	Development and Clinical Application of a Panfungal PCR Assay To Detect and Identify Fungal DNA in Tissue Specimens. Journal of Clinical Microbiology, 2007, 45, 380-385.	1.8	289
9	The Case for Adopting the "Species Complex―Nomenclature for the Etiologic Agents of Cryptococcosis. MSphere, 2017, 2, .	1.3	274
10	International Society of Human and Animal Mycology (ISHAM)-ITS reference DNA barcoding database—the quality controlled standard tool for routine identification of human and animal pathogenic fungi. Medical Mycology, 2015, 53, 313-337.	0.3	252
11	Molecular typing of global isolates ofCryptococcus neoformans var.neoformans by polymerase chain reaction fingerprinting and randomly amplified polymorphic DNA — a pilot study to standardize techniques on which to base a detailed epidemiological survey. Electrophoresis, 1999, 20, 1790-1799.	1.3	210
12	Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infectious Diseases, The, 2013, 13, 519-528.	4.6	198
13	Anti-Granulocyte-Macrophage Colony-Stimulating Factor Autoantibodies Are a Risk Factor for Central Nervous System Infection by Cryptococcus gattii in Otherwise Immunocompetent Patients. MBio, 2014, 5, e00912-14.	1.8	189
14	A prospective study of adverse reactions associated with vancomycin therapy. Journal of Antimicrobial Chemotherapy, 1985, 16, 235-241.	1.3	185
15	Not Just Little Adults: Candidemia Epidemiology, Molecular Characterization, and Antifungal Susceptibility in Neonatal and Pediatric Patients. Pediatrics, 2009, 123, 1360-1368.	1.0	171
16	Clinical Manifestations of Cryptococcus gattii Infection: Determinants of Neurological Sequelae and Death. Clinical Infectious Diseases, 2012, 55, 789-798.	2.9	171
17	Role of Extracellular Phospholipases and Mononuclear Phagocytes in Dissemination of Cryptococcosis in a Murine Model. Infection and Immunity, 2004, 72, 2229-2239.	1.0	152
18	Active Surveillance of Candidemia, Australia. Emerging Infectious Diseases, 2006, 12, 1508-1516.	2.0	151

#	Article	IF	CITATIONS
19	Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. Journal of Antimicrobial Chemotherapy, 2010, 65, 1042-1051.	1.3	148
20	Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. Journal of Antimicrobial Chemotherapy, 2006, 57, 628-638.	1.3	144
21	Antifungal agents. Medical Journal of Australia, 2007, 187, 404-409.	0.8	139
22	Hexadecylphosphocholine (Miltefosine) Has Broad-Spectrum Fungicidal Activity and Is Efficacious in a Mouse Model of Cryptococcosis. Antimicrobial Agents and Chemotherapy, 2006, 50, 414-421.	1.4	134
23	Candidemia in nonneutropenic critically ill patients: Risk factors for non-albicans Candida spp Critical Care Medicine, 2008, 36, 2034-2039.	0.4	134
24	Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality. Clinical Microbiology and Infection, 2015, 21, 490.e1-490.e10.	2.8	129
25	Cryptococcus gattii in North American Pacific Northwest: Whole-Population Genome Analysis Provides Insights into Species Evolution and Dispersal. MBio, 2014, 5, e01464-14.	1.8	126
26	Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. Lancet Infectious Diseases, The, 2017, 17, e344-e356.	4.6	124
27	An emergent clade of SARS-CoV-2 linked to returned travellers from Iran. Virus Evolution, 2020, 6, veaa027.	2.2	119
28	Antifungal Therapy and Management of Complications of Cryptococcosis due to Cryptococcus gattii. Clinical Infectious Diseases, 2013, 57, 543-551.	2.9	106
29	Proton Nuclear Magnetic ResonanceBased Metabonomics for Rapid Diagnosis of Meningitis and Ventriculitis. Clinical Infectious Diseases, 2005, 41, 1582-1590.	2.9	103
30	<i>KRE</i> genes are required for βâ€1,6â€glucan synthesis, maintenance of capsule architecture and cell wall protein anchoring in <i>Cryptococcus neoformans</i> . Molecular Microbiology, 2010, 76, 517-534.	1.2	103
31	Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clinical Microbiology and Infection, 2009, 15, 689-693.	2.8	102
32	Clinical Utility of the Cryptococcal Antigen Lateral Flow Assay in a Diagnostic Mycology Laboratory. PLoS ONE, 2012, 7, e49541.	1.1	102
33	Lipid Rafts in Cryptococcus neoformans Concentrate the Virulence Determinants Phospholipase B1 and Cu/Zn Superoxide Dismutase. Eukaryotic Cell, 2006, 5, 488-498.	3.4	101
34	Skull-base osteomyelitis: fungal vs. bacterial infection. Clinical Microbiology and Infection, 2011, 17, 306-311.	2.8	96
35	Clinical associations and prevalence of <i>Scedosporium</i> spp. in Australian cystic fibrosis patients: identification of novel risk factors?. Medical Mycology, 2010, 48, S37-S44.	0.3	93
36	Purification and characterization of secretory phospholipase B, lysophospholipase and lysophospholipase/transacylase from a virulent strain of the pathogenic fungus Cryptococcus neoformans. Biochemical Journal, 2000, 347, 431-439.	1.7	92

#	Article	IF	CITATIONS
37	Responding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside. Future Microbiology, 2018, 13, 1175-1191.	1.0	92
38	Comparison of Whole Blood, Serum, and Plasma for Early Detection of Candidemia by Multiplex-Tandem PCR. Journal of Clinical Microbiology, 2010, 48, 811-816.	1.8	91
39	CCMetagen: comprehensive and accurate identification of eukaryotes and prokaryotes in metagenomic data. Genome Biology, 2020, 21, 103.	3.8	91
40	Changing epidemiology of candidaemia in Australia. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw422.	1.3	89
41	Cryptococcal transmigration across a model brain blood-barrier: evidence of the Trojan horse mechanism and differences between Cryptococcus neoformans var. grubii strain H99 and Cryptococcus gattii strain R265. Microbes and Infection, 2016, 18, 57-67.	1.0	89
42	Epidemiology of paediatric invasive fungal infections and a caseâ€control study of risk factors in acute leukaemia or post stem cell transplant. British Journal of Haematology, 2010, 149, 263-272.	1.2	88
43	Antifungal therapy in invasive fungal infections. Current Opinion in Pharmacology, 2010, 10, 522-530.	1.7	85
44	Multiplex Tandem PCR: a Novel Platform for Rapid Detection and Identification of Fungal Pathogens from Blood Culture Specimens. Journal of Clinical Microbiology, 2008, 46, 3021-3027.	1.8	83
45	Mucormycosis in Australia: contemporary epidemiology and outcomes. Clinical Microbiology and Infection, 2016, 22, 775-781.	2.8	83
46	Role of prospective screening of blood for invasive aspergillosis by polymerase chain reaction in febrile neutropenic recipients of haematopoietic stem cell transplants and patients with acute leukaemia. British Journal of Haematology, 2005, 132, 051220022257011.	1.2	82
47	Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management. Clinical Microbiology and Infection, 2009, 15, 662-669.	2.8	79
48	Determinants of mortality in non-neutropenic ICU patients with candidaemia. Critical Care, 2009, 13, R115.	2.5	79
49	<i>Scedosporium prolificans</i> Osteomyelitis in an Immunocompetent Child Treated with a Novel Agent, Hexadecylphospocholine (Miltefosine), in Combination with Terbinafine and Voriconazole: A Case Report. Clinical Infectious Diseases, 2009, 48, 1257-1261.	2.9	78
50	Meta-transcriptomics reveals a diverse antibiotic resistance gene pool in avian microbiomes. BMC Biology, 2019, 17, 31.	1.7	76
51	Accurate and Practical Identification of 20 Fusarium Species by Seven-Locus Sequence Analysis and Reverse Line Blot Hybridization, and an In Vitro Antifungal Susceptibility Study. Journal of Clinical Microbiology, 2011, 49, 1890-1898.	1.8	75
52	Molecular Typing of Australian <i>Scedosporium</i> Isolates Showing Genetic Variability and Numerous <i>S. aurantiacum</i> . Emerging Infectious Diseases, 2008, 14, 282-290.	2.0	74
53	Detection of Occult <i>Scedosporium</i> Species in Respiratory Tract Specimens from Patients with Cystic Fibrosis by Use of Selective Media. Journal of Clinical Microbiology, 2010, 48, 314-316.	1.8	74
54	Cell Wall-linked Cryptococcal Phospholipase B1 Is a Source of Secreted Enzyme and a Determinant of Cell Wall Integrity. Journal of Biological Chemistry, 2007, 282, 37508-37514.	1.6	73

#	Article	IF	CITATIONS
55	The Crz1/Sp1 Transcription Factor of Cryptococcus neoformans Is Activated by Calcineurin and Regulates Cell Wall Integrity. PLoS ONE, 2012, 7, e51403.	1.1	73

## 56 Central Nervous System Cryptococcal Infections in Non-HIV Infected Patients. Journal of Fungi (Basel,) Tj ETQq0 0 Q rgBT /Overlock 10 T

57	Rapid Identification of Candida Species by Using Nuclear Magnetic Resonance Spectroscopy and a Statistical Classification Strategy. Applied and Environmental Microbiology, 2003, 69, 4566-4574.	1.4	70
58	Purification and characterization of secretory phospholipase B, lysophospholipase and lysophospholipase/transacylase from a virulent strain of the pathogenic fungus Cryptococcus neoformans. Biochemical Journal, 2000, 347, 431.	1.7	68
59	Practical Method for Detection and Identification of <i>Candida, Aspergillus</i> , and <i>Scedosporium</i> spp. by Use of Rolling-Circle Amplification. Journal of Clinical Microbiology, 2008, 46, 2423-2427.	1.8	67
60	Secretion of cryptococcal phospholipase B1 (PLB1) is regulated by a glycosylphosphatidylinositol (GPI) anchor. Biochemical Journal, 2005, 389, 803-812.	1.7	66
61	Phospholipase B activity enhances adhesion of Cryptococcus neoformans to a human lung epithelial cell line. Microbes and Infection, 2006, 8, 1006-1015.	1.0	66
62	Delivering on Antimicrobial Resistance Agenda Not Possible without Improving Fungal Diagnostic Capabilities. Emerging Infectious Diseases, 2017, 23, 177-183.	2.0	65
63	Rapid Identification and Differentiation of <i>Trichophyton</i> Species, Based on Sequence Polymorphisms of the Ribosomal Internal Transcribed Spacer Regions, by Rolling-Circle Amplification. Journal of Clinical Microbiology, 2008, 46, 1192-1199.	1.8	64
64	SARS-CoV-2 infection and COVID-19: The lived experience and perceptions of patients in isolation and care in an Australian healthcare setting. American Journal of Infection Control, 2020, 48, 1445-1450.	1.1	62
65	Metabolites released by Cryptococcus neoformans var. neoformans and var. gattii differentially affect human neutrophil function. Microbes and Infection, 2002, 4, 1427-1438.	1.0	61
66	In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens. Journal of Antimicrobial Chemotherapy, 2013, 68, 2842-2846.	1.3	61
67	Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014. Internal Medicine Journal, 2014, 44, 1315-1332.	0.5	61
68	Clinical features of endemic community-acquired psittacosis. New Microbes and New Infections, 2014, 2, 7-12.	0.8	61
69	Current status and future perspectives on molecular and serological methods in diagnostic mycology. Future Microbiology, 2009, 4, 1185-1222.	1.0	59
70	In Vitro Antifungal Activities of Inhibitors of Phospholipases from the Fungal Pathogen Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy, 2004, 48, 1561-1569.	1.4	58
71	Pulmonary Cryptococcosis. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 681-691.	0.8	58
72	Role and mechanism of phosphatidylinositolâ€specific phospholipase C in survival and virulence of <i>Cryptococcus neoformans</i> . Molecular Microbiology, 2008, 69, 809-826.	1.2	57

#	Article	IF	CITATIONS
73	PCR-Restriction Fragment Length Polymorphism Analysis of the Phospholipase B ( PLB1 ) Gene for Subtyping of Cryptococcus neoformans Isolates. Applied and Environmental Microbiology, 2003, 69, 2080-2086.	1.4	56
74	Cryptococcus gattii Virulence Composite: Candidate Genes Revealed by Microarray Analysis of High and Less Virulent Vancouver Island Outbreak Strains. PLoS ONE, 2011, 6, e16076.	1.1	56
75	Identification by Random Amplification of Polymorphic DNA of a Common Molecular Type of Cryptococcus neoformans var. neoformans in Patients with AIDS or Other Immunosuppressive Conditions. Journal of Infectious Diseases, 1996, 173, 754-757.	1.9	55
76	Cryptococcomas Distinguished from Gliomas with MR Spectroscopy: An Experimental Rat and Cell Culture Study. Radiology, 2001, 220, 122-128.	3.6	55
77	Candidemia following solid organ transplantation in the era of antifungal prophylaxis: the Australian experience. Transplant Infectious Disease, 2009, 11, 122-127.	0.7	55
78	Identification of metabolites of importance in the pathogenesis of pulmonary cryptococcoma using nuclear magnetic resonance spectroscopy. Microbes and Infection, 2003, 5, 285-290.	1.0	54
79	Antifungal agents for preventing fungal infections in solid organ transplant recipients. The Cochrane Library, 2004, , CD004291.	1.5	53
80	Identification of pathogenic yeasts of the imperfect genusCandida by polymerase chain reaction fingerprinting. Electrophoresis, 1997, 18, 1548-1559.	1.3	49
81	Reverse Line Blot Hybridization Assay for Identification of Medically Important Fungi from Culture and Clinical Specimens. Journal of Clinical Microbiology, 2007, 45, 2872-2880.	1.8	49
82	Rapid detection of ERG11 gene mutations in clinical Candida albicans isolates with reduced susceptibility to fluconazole by rolling circle amplification and DNA sequencing. BMC Microbiology, 2009, 9, 167.	1.3	49
83	Assessment of clinical risk predictive rules for invasive candidiasis in a prospective multicentre cohort of ICU patients. Intensive Care Medicine, 2009, 35, 2141-2145.	3.9	49
84	Miltefosine Induces Apoptosis-Like Cell Death in Yeast via Cox9p in Cytochrome <i>c</i> Oxidase. Molecular Pharmacology, 2011, 80, 476-485.	1.0	49
85	Identification of Novel Hybrids Between Cryptococcus neoformans var. grubii VNI and Cryptococcus gattii VGII. Mycopathologia, 2012, 173, 337-346.	1.3	49
86	Fungal Inositol Pyrophosphate IP <sub>7</sub> Is Crucial for Metabolic Adaptation to the Host Environment and Pathogenicity. MBio, 2015, 6, e00531-15.	1.8	49
87	MLST and Whole-Genome-Based Population Analysis of Cryptococcus gattii VGIII Links Clinical, Veterinary and Environmental Strains, and Reveals Divergent Serotype Specific Sub-populations and Distant Ancestors. PLoS Neglected Tropical Diseases, 2016, 10, e0004861.	1.3	49
88	Three-Locus Identification, Genotyping, and Antifungal Susceptibilities of Medically Important Trichosporon Species from China. Journal of Clinical Microbiology, 2011, 49, 3805-3811.	1.8	47
89	Guidelines for the use of antifungal agents in the treatment of invasiveCandidaand mould infections. Internal Medicine Journal, 2004, 34, 192-200.	0.5	46
90	Candida Colonization as a Risk Marker for Invasive Candidiasis in Mixed Medical-Surgical Intensive Care Units: Development and Evaluation of a Simple, Standard Protocol. Journal of Clinical Microbiology, 2015, 53, 1324-1330.	1.8	44

#	Article	IF	CITATIONS
91	In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi. Medical Mycology, 2018, 56, 1050-1054.	0.3	44
92	A comparison of hospital and community-acquired infective endocarditis. American Journal of Cardiology, 1992, 70, 1449-1452.	0.7	43
93	Development of a Nested Qualitative Real-Time PCR Assay To Detect Aspergillus Species DNA in Clinical Specimens. Journal of Clinical Microbiology, 2005, 43, 5366-5368.	1.8	43
94	Molecular diagnostic methods for invasive fungal disease: the horizon draws nearer?. Pathology, 2015, 47, 257-269.	0.3	43
95	Fungal-Derived Immune Modulating Molecules. Advances in Experimental Medicine and Biology, 2009, 666, 108-120.	0.8	42
96	Increasing incidence of candidaemia: long-term epidemiological trends, Queensland, Australia, 1999–2008. Journal of Hospital Infection, 2010, 76, 46-51.	1.4	42
97	Heteronuclear NMR studies of metabolites produced byCryptococcus neoformans in culture media: Identification of possible virulence factors. Magnetic Resonance in Medicine, 1999, 42, 442-453.	1.9	41
98	Opportunities and challenges to improving antibiotic prescribing practices through a One Health approach: results of a comparative survey of doctors, dentists and veterinarians in Australia. BMJ Open, 2018, 8, e020439.	0.8	41
99	Database establishment for the secondary fungal DNA barcode <i>translational elongation factor lî±</i> ( <i>TEF1î±</i> ). Genome, 2019, 62, 160-169.	0.9	41
100	Biochemical and Functional Characterisation of Secreted Phospholipase Activities from Cryptococcus Neoformans in their Naturally Occurring State. Journal of Medical Microbiology, 1999, 48, 731-740.	0.7	40
101	In Vitro Activities of Miltefosine and Two Novel Antifungal Biscationic Salts against a Panel of 77 Dermatophytes. Antimicrobial Agents and Chemotherapy, 2007, 51, 2219-2222.	1.4	40
102	Dual DNA Barcoding for the Molecular Identification of the Agents of Invasive Fungal Infections. Frontiers in Microbiology, 2019, 10, 1647.	1.5	40
103	Identification of Enterococcus, Streptococcus , and Staphylococcus by Multivariate Analysis of Proton Magnetic Resonance Spectroscopic Data from Plate Cultures. Journal of Clinical Microbiology, 2001, 39, 2916-2923.	1.8	39
104	Cryptococcal Lipid Metabolism: Phospholipase B1 Is Implicated in Transcellular Metabolism of Macrophage-Derived Lipids. Eukaryotic Cell, 2007, 6, 37-47.	3.4	39
105	Chitotriosidase and gene therapy for fungal infections. Cellular and Molecular Life Sciences, 2009, 66, 1116-1125.	2.4	38
106	<i>Cryptococcus gattii</i> infections: contemporary aspects of epidemiology, clinical manifestations and management of infection. Future Microbiology, 2013, 8, 1613-1631.	1.0	38
107	Identification of genetic markers of resistance to echinocandins, azoles and 5-fluorocytosine in Candida glabrata by next-generation sequencing: a feasibility study. Clinical Microbiology and Infection, 2017, 23, 676.e7-676.e10.	2.8	38
108	Inhibition of the human platelet cyclooxygenase response by the naturally occurring phenazine derivative, 1-hydroxyphenazine. Prostaglandins, 1995, 50, 301-311.	1.2	37

#	Article	IF	CITATIONS
109	Cryptococcal phospholipases: a novel lysophospholipase discovered in the pathogenic fungus Cryptococcus gattii. Biochemical Journal, 2004, 384, 377-384.	1.7	37
110	<i>secA1</i> Gene Sequence Polymorphisms for Species Identification of <i>Nocardia</i> Species and Recognition of Intraspecies Genetic Diversity. Journal of Clinical Microbiology, 2010, 48, 3928-3934.	1.8	37
111	The Early Innate Immune Response to, and Phagocyte-Dependent Entry of, Cryptococcus neoformans Map to the Perivascular Space of Cortical Post-Capillary Venules in Neurocryptococcosis. American Journal of Pathology, 2018, 188, 1653-1665.	1.9	37
112	Phospholipase C of Cryptococcus neoformans Regulates Homeostasis and Virulence by Providing Inositol Trisphosphate as a Substrate for Arg1 Kinase. Infection and Immunity, 2013, 81, 1245-1255.	1.0	36
113	Problematic Dichotomization of Risk for Intensive Care Unit (ICU)–Acquired Invasive Candidiasis: Results Using a Risk-Predictive Model to Categorize 3 Levels of Risk From a Multicenter Prospective Cohort of Australian ICU Patients. Clinical Infectious Diseases, 2016, 63, 1463-1469.	2.9	36
114	Surveillance for azole resistance in clinical and environmental isolates of Aspergillus fumigatus in Australia and cyp51A homology modelling of azole-resistant isolates. Journal of Antimicrobial Chemotherapy, 2018, 73, 2347-2351.	1.3	35
115	Identification ofStaphylococcus aureusBrain Abscesses: Rat and Human Studies with1H MR Spectroscopy. Radiology, 2005, 236, 261-270.	3.6	34
116	Simultaneous Detection and Identification of Candida, Aspergillus, and Cryptococcus Species by Reverse Line Blot Hybridization. Journal of Clinical Microbiology, 2006, 44, 876-880.	1.8	34
117	Clinician response to Candida organisms in the urine of patients attending hospital. European Journal of Clinical Microbiology and Infectious Diseases, 2008, 27, 201-208.	1.3	34
118	Pathogenesis of Pulmonary Cryptococcus gattii Infection: A Rat Model. Mycopathologia, 2010, 170, 315-330.	1.3	34
119	Pho4 Is Essential for Dissemination of Cryptococcus neoformans to the Host Brain by Promoting Phosphate Uptake and Growth at Alkaline pH. MSphere, 2017, 2, .	1.3	34
120	Correlation of Antifungal Activity with Fungal Phospholipase Inhibition Using a Series of Bisquaternary Ammonium Salts. Journal of Medicinal Chemistry, 2006, 49, 811-816.	2.9	33
121	Limited Activity of Miltefosine in Murine Models of Cryptococcal Meningoencephalitis and Disseminated Cryptococcosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 745-750.	1.4	33
122	Watersheds in planetary health research and action. Lancet Planetary Health, The, 2018, 2, e510-e511.	5.1	33
123	A rapid method for detecting extracellular proteinase activity in Cryptococcus neoformans and a survey of 63 isolates. Journal of Medical Microbiology, 2000, 49, 733-737.	0.7	33
124	Synthesis, antifungal and haemolytic activity of a series of bis(pyridinium)alkanes. Bioorganic and Medicinal Chemistry, 2007, 15, 3422-3429.	1.4	32
125	Rapid Etiological Classification of Meningitis by NMR Spectroscopy Based on Metabolite Profiles and Host Response. PLoS ONE, 2009, 4, e5328.	1.1	32
126	Pseudomonas aeruginosa Inhibits the Growth of Scedosporium and Lomentospora In Vitro. Mycopathologia, 2018, 183, 251-261.	1.3	32

8

#	Article	IF	CITATIONS
127	Synthesis, antifungal and antimicrobial activity of alkylphospholipids. Bioorganic and Medicinal Chemistry, 2007, 15, 5158-5165.	1.4	31
128	Whole Genome Sequencing of Australian Candida glabrata Isolates Reveals Genetic Diversity and Novel Sequence Types. Frontiers in Microbiology, 2018, 9, 2946.	1.5	31
129	Comparison of human polymorphonuclear leukocytes from peripheral blood and purulent exudates by high resolution1H MRS. Magnetic Resonance in Medicine, 1991, 19, 191-198.	1.9	30
130	The use of taxon-specific reference databases compromises metagenomic classification. BMC Genomics, 2020, 21, 184.	1.2	30
131	Colony Multiplex-Tandem PCR for Rapid, Accurate Identification of Fungal Cultures. Journal of Clinical Microbiology, 2008, 46, 4058-4060.	1.8	29
132	Identification of a major IP5 kinase in Cryptococcus neoformans confirms that PP-IP5/IP7, not IP6, is essential for virulence. Scientific Reports, 2016, 6, 23927.	1.6	29
133	Influenza A Virus as a Predisposing Factor for Cryptococcosis. Frontiers in Cellular and Infection Microbiology, 2017, 7, 419.	1.8	29
134	Prophylaxis, empirical and preemptive treatment of invasive candidiasis. Current Opinion in Critical Care, 2010, 16, 470-474.	1.6	28
135	Identification of Aph1, a Phosphate-Regulated, Secreted, and Vacuolar Acid Phosphatase in Cryptococcus neoformans. MBio, 2014, 5, e01649-14.	1.8	28
136	Long-read sequencing based clinical metagenomics for the detection and confirmation of Pneumocystis jirovecii directly from clinical specimens: A paradigm shift in mycological diagnostics. Medical Mycology, 2020, 58, 650-660.	0.3	28
137	Pneumonia and Lung Infections due to Emerging and Unusual Fungal Pathogens. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 703-716.	0.8	27
138	Cathelicidins in the Tasmanian devil (Sarcophilus harrisii). Scientific Reports, 2016, 6, 35019.	1.6	27
139	EXTRAPULMONARY TUBERCULOSIS A CONTINUING PROBLEM IN AUSTRALIA. Australian and New Zealand Journal of Medicine, 1987, 17, 507-511.	0.5	26
140	N-linked glycosylation sites affect secretion of cryptococcal phospholipase B1, irrespective of glycosylphosphatidylinositol anchoring. Biochimica Et Biophysica Acta - General Subjects, 2006, 1760, 1569-1579.	1.1	26
141	Association between fertility and molecular sub-type of global isolates ofCryptococcus gattiimolecular type VGII. Medical Mycology, 2008, 46, 665-673.	0.3	26
142	Parainfluenza Virus Type 3 Pneumonia in Bone Marrow Transplant Recipients: Multiple Small Nodules in Highâ€Resolution Lung Computed Tomography Scans Provide a Radiological Clue to Diagnosis. Clinical Infectious Diseases, 2009, 48, 905-909.	2.9	26
143	MSG07: An International Cohort Study Comparing Epidemiology and Outcomes of Patients With <i>Cryptococcus neoformans</i> or <i>Cryptococcus gattii</i> Infections. Clinical Infectious Diseases, 2021, 73, 1133-1141.	2.9	26
144	Production of metabolic products of arachidonic acid during cell-cell interactions. Journal of Allergy and Clinical Immunology, 1984, 74, 338-342.	1.5	24

#	Article	IF	CITATIONS
145	Isolation and characterisation of the phospholipase B gene ofCryptococcus neoformansvar.gattii. FEMS Yeast Research, 2002, 2, 551-561.	1.1	24
146	Antifungal susceptibilities of non-Aspergillus filamentous fungi causing invasive infection in Australia: support for current antifungal guideline recommendations. International Journal of Antimicrobial Agents, 2016, 48, 453-458.	1.1	24
147	Whole Genome Sequencing of <em>Candida glabrata</em> for Detection of Markers of Antifungal Drug Resistance. Journal of Visualized Experiments, 2017, , .	0.2	24
148	Assignment of Reference 5`-end 16S rDNA Sequences and Species-Specific Sequence Polymorphisms Improves Species Identification of Nocardia. Open Microbiology Journal, 2009, 3, 97-105.	0.2	24
149	The origin of 1H NMR-visible triacylglycerol in human neutrophils. FEBS Journal, 2000, 267, 68-78.	0.2	23
150	Risk factors for candidaemia: A prospective multiâ€centre caseâ€control study. Mycoses, 2021, 64, 257-263.	1.8	23
151	Changes in Cellular and Plasma Membrane Phospholipid Composition after Lipopolysaccharide Stimulation of Human Neutrophils, Studied by 31P NMR. FEBS Journal, 1997, 243, 328-335.	0.2	22
152	Antifungal Effects on Metabolite Profiles of Medically Important Yeast Species Measured by Nuclear Magnetic Resonance Spectroscopy. Antimicrobial Agents and Chemotherapy, 2006, 50, 4018-4026.	1.4	22
153	A rapid screening test to distinguish betweenCandida albicansandCandida dubliniensisusing NMR spectroscopy. FEMS Microbiology Letters, 2005, 251, 327-332.	0.7	21
154	Management of Invasive Candidiasis in the Intensive Care Unit. Drugs, 2010, 70, 823-839.	4.9	21
155	Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre(R) YeastOne(R) for Candida albicans: a prospective observational cohort study. Journal of Antimicrobial Chemotherapy, 2014, 69, 2210-2214.	1.3	21
156	IP <sub>7</sub> -SPX Domain Interaction Controls Fungal Virulence by Stabilizing Phosphate Signaling Machinery. MBio, 2020, 11, .	1.8	21
157	Synthesis, antifungal, haemolytic and cytotoxic activities of a series of bis(alkylpyridinium)alkanes. Bioorganic and Medicinal Chemistry, 2009, 17, 6329-6339.	1.4	20
158	Identification of Pathogenic Nocardia Species by Reverse Line Blot Hybridization Targeting the 16S rRNA and 16S-23S rRNA Gene Spacer Regions. Journal of Clinical Microbiology, 2010, 48, 503-511.	1.8	20
159	Whole-Genome Characterization and Genotyping of Global WU Polyomavirus Strains. Journal of Virology, 2010, 84, 6229-6234.	1.5	20
160	Metatranscriptomics as a tool to identify fungal species and subspecies in mixed communities – a proof of concept under laboratory conditions. IMA Fungus, 2019, 10, 12.	1.7	20
161	Consensus guidelines for the diagnosis and management of cryptococcosis and rare yeast infections in the haematology/oncology setting, 2021. Internal Medicine Journal, 2021, 51, 118-142.	0.5	19
162	Endocarditis associated with prosthetic cardiac valves. Medical Journal of Australia, 1990, 152, 458-463.	0.8	18

#	Article	IF	CITATIONS
163	Stimulation with lysates of Aspergillus terreus, Candida krusei and Rhizopus oryzae maximizes cross-reactivity of anti-fungal T cells. Cytotherapy, 2016, 18, 65-79.	0.3	18
164	Cerebral Nocardiosis Characterized by Magnetic Resonance Spectroscopy In Vivo. Clinical Infectious Diseases, 2002, 34, 849-852.	2.9	17
165	Nocardia Infections of the Face and Neck. Current Infectious Disease Reports, 2011, 13, 132-140.	1.3	17
166	Azoleâ€resistant <i>Aspergillus fumigatus</i> is highly prevalent in the environment of Vietnam, with marked variability by land use type. Environmental Microbiology, 2021, 23, 7632-7642.	1.8	17
167	Future directions for public health research in emerging infectious diseases. Public Health Research and Practice, 2016, 26, .	0.7	17
168	Quantitation of sulfidopeptide leukotrienes by reversed-phase high-performance liquid chromatography. Biomedical Applications, 1985, 343, 213-218.	1.7	16
169	GMP-140 (P-selectin) inhibits human neutrophil activation by lipopolysaccharide: Analysis by proton magnetic resonance spectroscopy. Biochemical and Biophysical Research Communications, 1992, 183, 1062-1069.	1.0	16
170	Improved identification of Gordonia, Rhodococcus and Tsukamurella species by 5'-end 16S rRNA gene sequencing. Pathology, 2011, 43, 58-63.	0.3	16
171	Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies. Leukemia and Lymphoma, 2011, 52, 179-193.	0.6	16
172	Rapid Microscopy and Use of Vital Dyes: Potential to Determine Viability of Cryptococcus neoformans in the Clinical Laboratory. PLoS ONE, 2015, 10, e0117186.	1.1	16
173	Marsupial and monotreme cathelicidins display antimicrobial activity, including against methicillin-resistant Staphylococcus aureus. Microbiology (United Kingdom), 2017, 163, 1457-1465.	0.7	16
174	Clinical Perspectives on <i>Cryptococcus neoformans</i> and <i>Cryptococcus gattii</i> : Implications for Diagnosis and Management. , 0, , 595-606.		16
175	Pseudomonas aeruginosa bacteraemia. Medical Journal of Australia, 1993, 159, 592-597.	0.8	15
176	Oxidative Stress and the Mobilisation of Arachidonic Acid in Stimulated Human Platelets: Role of Hydroxyl Radical. Prostaglandins, 1997, 54, 493-510.	1.2	15
177	One world, one health: beyond the Millennium Development Goals. Lancet, The, 2012, 380, 805-806.	6.3	15
178	Human rhinovirus C in adult haematopoietic stem cell transplant recipients with respiratory illness. Journal of Clinical Virology, 2013, 56, 339-343.	1.6	15
179	Functional disruption of yeast metacaspase, Mca1, leads to miltefosine resistance and inability to mediate miltefosine-induced apoptotic effects. Fungal Genetics and Biology, 2014, 67, 71-81.	0.9	15
180	Strain-dependent effects of environmental signals on the production of extracellular phospholipase byCryptococcus neoformans. FEMS Microbiology Letters, 2002, 209, 175-181.	0.7	14

#	Article	IF	CITATIONS
181	Synthesis and Evaluation of a Series of Bis(pentylpyridinium) Compounds as Antifungal Agents. ChemMedChem, 2018, 13, 1421-1436.	1.6	14
182	3 Human immunodeficiency virus infection in pregnancy. Bailliere's Clinical Obstetrics and Gynaecology, 1993, 7, 45-74.	0.6	13
183	Diagnosis of cerebral cryptococcoma using a computerized analysis of 1H NMR spectra in an animal model. Diagnostic Microbiology and Infectious Disease, 2005, 52, 101-105.	0.8	13
184	Inositol Polyphosphate Kinases, Fungal Virulence and Drug Discovery. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT	/Overlock	10 Tf 50 622
185	Cloning of CnLYSO1, a novel extracellular lysophospholipase of the pathogenic fungus Cryptococcus neoformans. Gene, 2003, 316, 67-78.	1.0	12
186	Cryptococcus neoformans: Latency and Disease. , 2014, , 429-439.		12
187	IP <sub>3-4</sub> kinase Arg1 regulates cell wall homeostasis and surface architecture to promote <i>Cryptococcus neoformans</i> infection in a mouse model. Virulence, 2017, 8, 1833-1848.	1.8	12
188	Identification and Characterization of VNI/VNII and Novel VNII/VNIV Hybrids and Impact of Hybridization on Virulence and Antifungal Susceptibility Within the C. neoformans/C. gattii Species Complex. PLoS ONE, 2016, 11, e0163955.	1.1	12
189	Drug-Resistant Aspergillus flavus Is Highly Prevalent in the Environment of Vietnam: A New Challenge for the Management of Aspergillosis?. Journal of Fungi (Basel, Switzerland), 2020, 6, 296.	1.5	11
190	Monitoring Glycolysis and Respiration Highlights Metabolic Inflexibility of Cryptococcus neoformans. Pathogens, 2020, 9, 684.	1.2	11
191	Trehalose as quantitative biomarker for in vivo diagnosis and treatment follow-up in cryptococcomas. Translational Research, 2021, 230, 111-122.	2.2	11
192	Circulating Polymorphonuclear Leukocytes from Patients with Gram-Negative Bacteremia Are Not Primed for Enhanced Production of Leukotriene B4 or 5-Hydroxyeicosatetraenoic Acid. Journal of Infectious Diseases, 1994, 169, 1151-1154.	1.9	10
193	<i>In Vitro</i> Antifungal Activities of Bis(Alkylpyridinium)Alkane Compounds against Pathogenic Yeasts and Molds. Antimicrobial Agents and Chemotherapy, 2010, 54, 3233-3240.	1.4	10
194	Fungal Kinases With a Sweet Tooth: Pleiotropic Roles of Their Phosphorylated Inositol Sugar Products in the Pathogenicity of Cryptococcus neoformans Present Novel Drug Targeting Opportunities. Frontiers in Cellular and Infection Microbiology, 2019, 9, 248.	1.8	10
195	Improving emergency preparedness and response in the Asia-Pacific. BMJ Global Health, 2019, 4, e001271.	2.0	10
196	Detection of antibodies to phospholipase B in patients infected withCryptococcus neoformansby enzyme-linked immunosorbent assay (ELISA). Medical Mycology, 2005, 43, 335-341.	0.3	9
197	Role of Conserved Active Site Residues in Catalysis by Phospholipase B1 from Cryptococcus neoformans. Biochemistry, 2007, 46, 10024-10032.	1.2	9
198	Building quality in health — the need for clinical researchers*. Medical Journal of Australia, 2009, 190, 627-629.	0.8	9

#	Article	IF	CITATIONS
199	Functional characterization of the hexose transporter Hxt13p: An efflux pump that mediates resistance to miltefosine in yeast. Fungal Genetics and Biology, 2013, 61, 23-32.	0.9	9
200	The Genus Scedosporium and Pseudallescheria: Current Challenges in Laboratory Diagnosis. Current Clinical Microbiology Reports, 2014, 1, 27-36.	1.8	9
201	Network properties of salmonella epidemics. Scientific Reports, 2019, 9, 6159.	1.6	9
202	Aspergillus and Penicillium. , 0, , 2030-2056.		9
203	Inhibition of Platelet Eicosanoid Metabolism by the Bacterial Phenazine Derivative Pyocyanin. Annals of the New York Academy of Sciences, 1994, 744, 320-322.	1.8	8
204	Application of proton nuclear magnetic resonance spectroscopy to the study ofCryptococcusand cryptococcosis. FEMS Yeast Research, 2006, 6, 558-566.	1.1	8
205	Reverse line blot hybridization and DNA sequencing studies of the 16S-23S rRNA gene intergenic spacer regions of five emerging pathogenic Nocardia species. Journal of Medical Microbiology, 2010, 59, 548-555.	0.7	8
206	Nocardia Species. , 2015, , 2853-2863.e2.		8
207	Genome-wide networks reveal emergence of epidemic strains of Salmonella Enteritidis. International Journal of Infectious Diseases, 2022, 117, 65-73.	1.5	8
208	Optimizing Therapy for Candida Infections. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 678-688.	0.8	7
209	Practical identification of eight medically important <i>Trichosporon</i> species by reverse line blot hybridization (RLB) assay and rolling circle amplification (RCA). Medical Mycology, 2013, 51, 300-308.	0.3	7
210	Infection control professionals' and infectious diseases physicians' knowledge, preparedness, and experiences of managing COVID-19 in Australian healthcare settings. Infection, Disease and Health, 2021, 26, 249-257.	0.5	7
211	Antibiotic exposure within six months before systemic therapy was associated with lower cancer survival. Journal of Clinical Epidemiology, 2022, 147, 122-131.	2.4	7
212	Phenytoin Sensitivity in a Case of Phenytoinâ€Associated Hodgkin's Disease*. Australian and New Zealand Journal of Medicine, 1975, 5, 144-147.	0.5	6
213	Koala cathelicidin PhciCath5 has antimicrobial activity, including against Chlamydia pecorum. PLoS ONE, 2021, 16, e0249658.	1.1	6
214	Impact of antifungal resistance in Australia. Microbiology Australia, 2007, 28, 174.	0.1	5
215	Vulnerability, hysteria and fear — conquering Ebola virus. Medical Journal of Australia, 2014, 201, 320-321.	0.8	5
216	The role of nuclear magnetic resonance in medical mycology. Current Fungal Infection Reports, 2008, 2, 149-156.	0.9	4

#	Article	IF	CITATIONS
217	Diagnosis of Barmah Forest Virus Infection by a Nested Real-Time SYBR Green RT-PCR Assay. PLoS ONE, 2013, 8, e65197.	1.1	4
218	A planetary health approach to emerging infections in Australia. Lancet, The, 2017, 389, 1293.	6.3	4
219	Nuclear Magnetic Resonance Spectroscopy-Based Identification of Yeast. Methods in Molecular Biology, 2017, 1508, 289-304.	0.4	4
220	Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt. Clinical Infectious Diseases, 2006, 43, 1031-1039.	2.9	3
221	Multiplex-Tandem PCR for Fungal Diagnostics. Methods in Molecular Biology, 2013, 968, 195-201.	0.4	3
222	Detection of Multiple Fungal Species in Blood Samples by Real-Time PCR: an Interpretative Challenge. Journal of Clinical Microbiology, 2014, 52, 3515-3516.	1.8	3
223	<scp>COVID</scp> â€19 in Australia: our national response to the first cases of <scp>SARSâ€CoV</scp> â€2 infection during the early biocontainment phase. Internal Medicine Journal, 2021, 51, 42-51.	0.5	3
224	Recent advances in management of cryptococcal meningitis: commentary. F1000 Medicine Reports, 2010, 2, 82.	2.9	3
225	Inferring evolutionary pathways and directed genotype networks of foodborne pathogens. PLoS Computational Biology, 2020, 16, e1008401.	1.5	3
226	Infectious diseases. Medical Journal of Australia, 1995, 162, 104-106.	0.8	2
227	Isolation and characterisation of the phospholipase B gene of var FEMS Yeast Research, 2002, 2, 551-561.	1.1	2
228	Cryptococcal phospholipase B antigen is not detected in serum of patients infected withCryptococcus neoformansusing a sandwich enzyme-linked immunosorbent assay. FEMS Yeast Research, 2007, 7, 465-470.	1.1	2
229	Is Australia prepared for the next pandemic?. Medical Journal of Australia, 2017, 206, 284-286.	0.8	2
230	Signaling Cascades and Enzymes as Cryptococcus Virulence Factors. , 0, , 217-234.		2
231	Complexity of Magnetic Resonance Spectrum Classification. , 2006, , 241-248.		2
232	HOST DEFENCES IN THE UPPER GENITAL TRACT OF THE FEMALE: STUDIES IN A MURINE SYSTEM. The Australian Journal of Experimental Biology and Medical Science, 1983, 61, 287-299.	0.7	1
233	Doing the right thing for tuberculosis control in the Torres Strait Islands. Medical Journal of Australia, 2011, 195, 512-512.	0.8	1
234	Urgent strategic research into influenza to inform health policy and protect the public. Medical Journal of Australia, 2006, 185, S77-9.	0.8	0

#	Article	IF	CITATIONS
235	Detection of Fungal Metabolites. Infectious Disease and Therapy, 2007, , 121-132.	0.0	Ο
236	Medical and veterinary mycology. Microbiology Australia, 2015, 36, 42.	0.1	0
237	Modern technology and infectious diseases activity data: how can we use this for service planning?. Internal Medicine Journal, 2015, 45, 688-688.	0.5	0
238	Developing research priorities for Australia's response to infectious disease emergencies. Communicable Diseases Intelligence, 2017, 41, E1-E3.	0.5	0
239	Inferring evolutionary pathways and directed genotype networks of foodborne pathogens. , 2020, 16, e1008401.		Ο
240	Inferring evolutionary pathways and directed genotype networks of foodborne pathogens. , 2020, 16, e1008401.		0
241	Inferring evolutionary pathways and directed genotype networks of foodborne pathogens. , 2020, 16, e1008401.		0
242	Inferring evolutionary pathways and directed genotype networks of foodborne pathogens. , 2020, 16, e1008401.		0
243	Inferring evolutionary pathways and directed genotype networks of foodborne pathogens. , 2020, 16, e1008401.		0
244	Inferring evolutionary pathways and directed genotype networks of foodborne pathogens. , 2020, 16, e1008401.		0